Guangzhou Pharmaceutical Yigan Biological Products

Guangzhou Pharmaceutical Yigan Biological Products is a Chinese biotechnology company focused on the development of biological therapeutics, specifically targeting infectious diseases. As a subsidiary of Guangzhou Baiyunshan Pharmaceutical Holdings, the company is most notable for its research into a therapeutic vaccine for chronic hepatitis B. This lead program, developed in collaboration with Southern Medical University, utilized recombinant protein technology to stimulate the immune system against the hepatitis B virus. Although the vaccine reached Phase IIb clinical trials, it encountered significant hurdles in meeting primary efficacy endpoints. The company continues to operate as a specialized biological research unit within its parent organization's extensive pharmaceutical portfolio.